Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug.
暂无分享,去创建一个
Frank Bates | Dennis E Discher | F. Bates | D. Discher | F. Ahmed | T. Minko | R. I. Pakunlu | Aaron K. Brannan | Refika I Pakunlu | Tamara Minko | Fariyal Ahmed | Aaron Brannan | Refika I. Pakunlu
[1] D. Gustafson,et al. Pharmacokinetics of combined doxorubicin and paclitaxel in mice. , 2005, Cancer letters.
[2] F. Szoka,et al. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. , 1982, European journal of cancer & clinical oncology.
[3] M. Lafleur,et al. On the characterization of pH-sensitive liposome/polymer complexes. , 2003, Biomacromolecules.
[4] Robert Langer,et al. Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance. , 2005, Biomaterials.
[5] R. Verger,et al. Hydrolysis kinetics of poly(d,l-lactide) monolayers spread on basic or acidic aqueous subphases , 1997 .
[6] Y. Oyama,et al. Cremophor EL, a non-ionic surfactant, promotes Ca(2+)-dependent process of cell death in rat thymocytes. , 2005, Toxicology.
[7] K. Maruyama,et al. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.
[8] K. Edwards,et al. Formation of transition metal-doxorubicin complexes inside liposomes. , 2002, Biochimica et biophysica acta.
[9] S. Agelaki,et al. Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors , 2002, Oncology.
[10] R. Staugas,et al. Peripheral Intravenous Line Survival and Phlebitis Prevention in Patients Receiving Intravenous Antibiotics: Heparin/Hydrocortisone versus In-Line Filters , 1994, The Annals of pharmacotherapy.
[11] F. Chang,et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] Fenghua Meng,et al. Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[13] John W. Park. Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.
[14] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[15] Daniel A. Hammer,et al. Molecular Weight Dependence of Polymersome Membrane Structure, Elasticity, and Stability , 2002 .
[16] I. Tannock,et al. Reduction of Intracellular pH as a Strategy to Enhance the pH-Dependent Cytotoxic Effects of Melphalan for Human Breast Cancer Cells , 2005, Clinical Cancer Research.
[17] Yang Wang,et al. Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense , 2004, Cancer Research.
[18] F. Szoka,et al. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. , 2001, Bioconjugate chemistry.
[19] J. Kopeček,et al. Efficacy of the chemotherapeutic action of HPMA copolymer‐bound doxorubicin in a solid tumor model of ovarian carcinoma , 2000, International journal of cancer.
[20] H. Gogas,et al. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group , 2004, British Journal of Cancer.
[21] F. Bates,et al. Polymer vesicles in vivo: correlations with PEG molecular weight. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[22] Sérgio Simões,et al. On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.
[23] N. Pavlidis,et al. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel , 2004, Cancer Chemotherapy and Pharmacology.
[24] Theresa M Allen,et al. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. , 2003, Biochimica et biophysica acta.
[25] J. Klaveness,et al. Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[26] Francis C Szoka,et al. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. , 2002, Bioconjugate chemistry.
[27] Christine Allen,et al. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. , 2004 .
[28] M. Bally,et al. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.
[29] Dennis E Discher,et al. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[30] J. Gehl,et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] F. Dosio,et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[32] N. Pavlidis,et al. Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] K. Belguise,et al. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells , 2005, Oncogene.
[34] D. Tzemach,et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .